Form 4: SIGA EVP & CSO's Routine Equity Transactions

SIGA Technologies' EVP & Chief Scientific Officer, Dennis E. Hruby, reported the vesting of restricted stock units and a new RSU grant, alongside shares withheld for tax obligations.

Summary

• Dennis E. Hruby, EVP & Chief Scientific Officer of SIGA Technologies Inc. (SIGA), reported equity transactions on March 13, 2026.
• Acquired 11,445 shares of Common Stock from the vesting of one-third of Restricted Stock Units (RSUs) granted on March 13, 2025.
• Disposed of 3,955 shares of Common Stock at a price of $5.26 per share to satisfy tax withholding obligations associated with the RSU vesting.
• Received a new grant of 54,942 Restricted Stock Units (RSUs).
• Following these transactions, Hruby directly owns 198,537 shares of Common Stock and 54,942 new RSUs, in addition to 22,891 remaining RSUs from the prior grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued insider alignment through equity holdings, without indicating any significant operational changes or market shifts.

Positives

• Insider, Dennis E. Hruby, continues to hold a significant number of common shares (198,537) and derivative securities (77,833 RSUs), aligning his interests with shareholders.
• The grant of 54,942 new Restricted Stock Units (RSUs) indicates continued long-term incentive for a key executive.

Negatives

• 3,955 shares were disposed of to cover tax liabilities, which is a common practice but reduces direct share ownership.

Future Outlook

The newly granted 54,942 Restricted Stock Units (RSUs) will vest over three years, with one-third vesting on each of the first three anniversaries of the grant date (March 13, 2026). The remaining 22,891 RSUs from the March 13, 2025 grant will also continue to vest over their original schedule.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common in the biotechnology and pharmaceutical sectors, reflecting standard executive compensation practices. The grant of new RSUs is a typical mechanism to incentivize long-term executive performance and retention.

Comparison to Industry Standards

• The RSU vesting and tax withholding are standard practices for executive compensation in publicly traded companies, aligning with typical equity incentive plans seen across the S&P 500.
• The grant of new RSUs is a common method for executive retention and performance alignment, comparable to practices at peer companies in the biotech space like Moderna (MRNA) or BioNTech (BNTX), which frequently use equity awards to compensate key scientific and executive personnel.

Stakeholder Impact

• Shareholders: The vesting and new grant of RSUs align executive interests with long-term shareholder value. The sale of shares for tax purposes is a minor, routine dilution.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent for other equity-holding employees.

Next Steps

• Future vesting of the remaining 22,891 Restricted Stock Units (RSUs) from the March 13, 2025 grant.
• Future vesting of the newly granted 54,942 Restricted Stock Units (RSUs) over the next three years.

Key Dates

Keywords

SIGA Technologies, SIGA, Dennis E. Hruby, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU vesting, executive compensation, equity grant